Conditions: Breast Cancer Ovarian Cancer Endometrial Cancer Cervical Cancer
Keywords: Breast Ovarian Endometrial Cervical Metastatic 852A IRM Oncology Metastatic Cervical Cancer Metastatic Ovarian Cancer Metastatic Breast Cancer Metastatic Endometrial Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.

Detailed description:
852A will be administered as a subcutaneous injection (SC) 2 times per week for 12 weeks (24 doses) with provisions for dose escalation or reduction based on tolerability.

Arms:
arm 1: Patients treated with at least one dose - 852A subcutaneous injection. arm 2: Patients who received all 24 doses of 852A per protocol.

Interventions: intervention 1: 852A
Intervention descriptions: intervention 1: 0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.

Protocol document: